Company: PRME
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001193125-25-122158
Chunk: 9

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 9
---
 Disease and CF; its expectations regarding the breadth of
Prime Editing technology and the implementation of its strategic plans for its business, programs, and technology; the potential of Prime Editing as a transformative gene editing technology and its ability to unlock opportunities across thousands of
potential indications; and its ability to identify an external partner to deliver PM359 therapy in X-linked CGD to patients; its evaluation of potential business development opportunities, including its
ability to execute and realize the anticipated benefits of any strategic alternatives it may pursue; the impact of the pipeline deprioritization; and its expectations regarding the arbitration proceedings with Beam Therapeutics, Inc. The words
“may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,”
“estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained in this Current Report on
Form 8-K, such as those related to arbitration proceedings with Beam, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K. These
and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the year ended
December 31, 2024, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of today and should not be relied upon as
representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any
such forward-looking statements except as required by law.

| Item 9.01 | Financial Statements and Exhibits. |

(d) Exhibits

| Exhibit 
 No.     
 99.1    
 99.2    |     | Description                                                                 
 Press Release issued by the Company on May 19, 2025, furnished herewith.    
 Press Release issued by the Company on May 19, 2025,